Prostate Cancer Clinical Trial
Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer
Summary
This phase II trial studies how well focal radiation therapy with stereotactic body radiation therapy (SBRT) or high-dose rate (HDR) brachytherapy works in treating patients with low or intermediate-risk prostate cancer. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. HDR brachytherapy uses high doses of radiation to target these tumor cells. Giving focal radiation therapy with SBRT or HDR brachytherapy may target dominant tumor cells while sparing the reminder of the prostate or surrounding normal organs and ultimately reduce side effects while maintaining disease control.
Full Description
PRIMARY OBJECTIVES:
I. Evaluate biochemical progression free survival (bPFS) using the Phoenix definition.
II. Changes in quality of life. IIa. Prostate-Quality of Life (PR-QOL). IIb. Expanded Prostate Cancer Index Composite (EPIC).
SECONDARY OBJECTIVES:
I. Prostate-specific antigen (PSA) response at 3, 6, 12, and 24 months. II. Clinical progression free survival. IIa. Including phoenix definition, local progression by Response Evaluation Criteria in Solid Tumors (RECIST), regional progression, distant metastasis, or death.
III. Distant metastasis free survival. IV. Development of castration-resistant disease. V. Overall survival.
OUTLINE: Patients are assigned to 1 of 2 arms.
ARM I: Patients undergo SBRT in 5 fractions over 14 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients undergo HDR brachytherapy on day 1 and a second fraction within 14 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 6 weeks, every 3 months for up to 24 months, every 6 months for up to 60 months, and then every 8-12 months until 120 months.
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed diagnosis of prostate adenocarcinoma within 90 days prior to registration via systematic biopsy and with the following low/intermediate-risk features:
cT1c - T2b
PSA =< 15
< 50% cores positive
Gleason score (GS) =< 7 (3+4 and 4+3 included)
Multiparametric magnetic resonance imaging (MRI) (mp-MRI) confirmed lesion(s) with only one lobe involvement of the prostate
Unilateral disease on systematic biopsy
No distant or locally advanced disease on standard staging exams as indicated
Bone scan and abdominopelvic computed tomography (CT)/MRI OR
Prostate specific membrane antigen (PSMA) positron emission tomography (PET)
Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status 0/1 within 60 days prior to enrollment
Exclusion Criteria:
Gleason score >= 8
Gross extracapsular extension
Seminal vesicle invasion
Radiographic nodal or distant metastatic disease
Androgen deprivation therapy within 90 days of enrollment
Lesion(s) comprising > 40% of total prostate volume
Lesion < 0.5 cm from urethra
Prior radical prostatectomy
Prior radiotherapy to the pelvis
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Los Angeles California, 90095, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.